Fascinating innovation by @sjohnliu Lab, published in @JNeurooncol: reprogramming glioblastoma cells to overcome temozolomide resistance using CRISPRoff. Especially intrigued by this: “unlike conventional CRISPR–Cas9-based gene editing, the CRISPRoff-induced epigenetic changes are reversible, possibly resulting in an improved safety profile.”